Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
| Distributed by / for | Golden State Medical Supply Inc. |
| NDC | 60429-317-30 |
| Full product label | Losartan Potassium, 50 mg tablets, 30 count bottle, NDC 60429-317-30 |
| Recalling firm | Golden State Medical Supply Inc. |
| Distribution | US Nationwide One (1) US government account. No foreign accounts. |
| Quantity | 4,037 bottles (121,110 tablets) |
| Recall initiated | 2019-06-14 |
| Report date | 2019-07-17 |
| Recall completed | 2020-02-19 |
| Recall number | D-1462-2019 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Camarillo CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗